Just days after the acquisition of agricultural microRNA firm Rosetta Green by Monsanto was cleared by Israeli antitrust authorities, Rosetta Green’s former parent from Rosetta Genomics has opposed the deal.

According to a Rosetta Green filing with Israeli regulators, Rosetta Genomics argued that the transaction would inappropriately give Monsanto access to proprietary software-related intellectual property that had been licensed to Rosetta Green.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.